Novabay Pharmaceuticals Inc FCF yield
What is the FCF yield of Novabay Pharmaceuticals Inc?
The FCF yield of Novabay Pharmaceuticals Inc is -87.25%
What is the definition of FCF yield?
Free cash flow yield (FCF yield) is a financial ratio that compares the free cash flow per share to the market value per share. The ratio is calculated by dividing free cash flow per share by the current share price.
ttm (trailing twelve months)
Free cash flow yield is a good measure of the company’s cash flow in respect to the company’s size. Larger companies tend to have a higher cash flow yield, but it’s not always the case. The higher the free cash flow yield, the more cash the company is generating that can be quickly accessed to satisfy its obligations. The lower the free cash flow yield, the more money investors are putting into the company with little result. The higher the ratio, the more attractive the investment is as it suggests that investors are paying less for each unit of free cash flow.
Free cash flow acts as an indicator of how capable a company is of repaying all of its obligations. It is a solid indicator of how financially stable a company is. It is calculated as:
Free cash flow yield = Free cash flow per share / market price per share
FCF yield of companies in the Health Care sector on NYSEMKT compared to Novabay Pharmaceuticals Inc
What does Novabay Pharmaceuticals Inc do?
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Companies with fcf yield similar to Novabay Pharmaceuticals Inc
- Eve & Co has FCF yield of -87.69%
- Arbuthnot Banking PLC has FCF yield of -87.63%
- Quadro Resources has FCF yield of -87.58%
- Earth Alive Clean Technologies has FCF yield of -87.57%
- Bancolombia S.A has FCF yield of -87.49%
- Avocent Corp has FCF yield of -87.41%
- Novabay Pharmaceuticals Inc has FCF yield of -87.25%
- SPI Co Ltd has FCF yield of -87.08%
- Arctic Star Exploration has FCF yield of -87.06%
- Cemtrex has FCF yield of -86.86%
- Pilot has FCF yield of -86.76%
- SpareBank 1 Ostlandet has FCF yield of -86.73%
- Panda Green has FCF yield of -86.68%